-
Mashup Score: 42Best Practice for RET NSCLC | IASLC - 1 day(s) ago
Host Dr. Stephen Liu moderates a discussion on RET as a therapeutic target in this episode of Lung Cancer Considered. RET fusions are a known actionable alterat …
Source: www.iaslc.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer - 2 day(s) ago
Mesenchymal-epithelial transition factor (MET) pathway dysregulation may occur through various mechanisms including MET overexpression, MET gene amplification, or MET exon 14 skipping (METex14) mutations [1–3]. Dysregulated MET is an established oncogenic driver in non–small cell lung cancer (NSCLC) [1,4–7]. In addition to its role in tumor cells, MET signaling may also modulate immune function leading to suppression of anticancer immune responses and MET overexpression or activation could play a role in tumor immune evasion [8–13].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 67Decoding Biomarker Testing and Targeted Therapy in NSCLC: The Complete Guide for 2024 - 3 day(s) ago
See the latest #TargetedTherapy #NSCLC live event from @PeerView, @StephenVLiu, @benlevylungdoc, @JessicaJLinMD, @peters_solange #ASCO24 #MedEd
Source: lrn.peerview.comCategories: General Medicine News, Hem/OncsTweet-
Saturday, June 1, 7pm CDT at #ASCO24 - join Drs. @benlevylungdoc @JessicaJLinMD @peters_solange and me for a free comprehensive #CME symposium on targeted therapy in NSCLC. We cover it all in 90min! Register now, live/virtual: https://t.co/qXn1MkYSgm [https://t.co/1YOhTYaQSq] https://t.co/pLU8XEql76
-
-
Mashup Score: 12Membership | IASLC - 4 day(s) ago
The only international society dedicated solely to lung cancer research, education, and patient care, we are the IASLC.
Source: www.iaslc.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 120
The Investor Relations website contains information about Merus’s business for stockholders, potential investors, and financial analysts.
Source: ir.merus.nlCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 59
Subcutaneous atezolizumab is approved for the treatment of various solid tumors. Previous results from the IMscin001 study (NCT03735121) demonstrated that the pharmacokinetics, efficacy, immunogenicity, and safety of subcutaneous and intravenous atezolizumab were consistent (data cutoff: April 26, 2022). We present updated data from this trial (data cut-off: 16 January 2023).
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 24
MedStar Health, D.C. Lung Cancer Conference 2024, 10/19/2024 7:30:00 AM – 10/19/2024 5:00:00 PM, This one-day multidisciplinary conference will provide a comprehensive update on recent clinical advances in lung cancer. The field is evolving very rapidly and over the past few years, there have been major shifts in our understanding of this highly lethal disease. We have seen high impact advances in all aspects of lung cancer management: from detection to diagnosis to treatment. The D.C. Lung Cancer Conference will emphasize current best practices for busy clinicians who care for patients with lung cancer, across disciplines. High impact, engaging didactic lectures will be delivered by international thought leaders and well-respected faculty in each field. An opening talk from a patient advocate will provide an important perspective. There will be updates on CT screening, proper use of liquid biopsy, interpretation of molecular testing results and review of smoking cessation techniques.
Source: medstar.cloud-cme.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 64
Trastuzumab deruxtecan showed anti-tumour activity and durable responses in heavily pretreated patients across multiple tumour types with activating HER2 mutations, with no new safety signals. Prespecified HER2 mutations might be targeted by HER2-directed antibody–drug conjugates and our findings support further investigation of trastuzumab deruxtecan in the pan-tumour setting.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 57
Trastuzumab deruxtecan showed anti-tumour activity and durable responses in heavily pretreated patients across multiple tumour types with activating HER2 mutations, with no new safety signals. Prespecified HER2 mutations might be targeted by HER2-directed antibody–drug conjugates and our findings support further investigation of trastuzumab deruxtecan in the pan-tumour setting.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 68National Cancer Institute Renews Georgetown Lombardi Top Designation - Lombardi Comprehensive Cancer Center - 10 day(s) ago
Breaking News:Georgetown’s Cancer Center Awarded Top Designation by Federal Government Designation as Comprehensive Cancer Center Consortium Includes John Theurer Cancer Center The National Cancer Institute (NCI), a part of the National Institutes of Health, has awarded its most prestigious designation — “comprehensive cancer center” status — to Georgetown University‘s Lombardi Comprehensive Cancer Center in recognition […]
Source: lombardi.georgetown.eduCategories: General Medicine News, Hem/OncsTweet
For the latest updates on targeting #RET in lung cancer, listen to this episode of the @IASLC podcast, Lung Cancer Considered, where I discuss the current standards and future directions of the field with Drs. @mihaela_aldea and @GautschiOliver. #LCSM https://t.co/OhXxFqO7hI